RxDoctor Payments Data

Mark Yazid, MD

Plastic and Reconstructive Surgery · Red Bank, NJNPI 1134532005

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,623 of the $4,815 with a category attached, or 75.3%. 18 manufacturers reported payments, led by AbbVie at 53.1% of the total. Reporting peaked in 2023 at $1,409 and has fallen 57.9% since, to $592 in 2025.

$4,815in general payments, 2019–2025

Across 66 payments — averaging $72.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Arthrex$1K
  • Integra Lifesciences Corporation$280
  • Seapearl East, Inc$153
  • Medtronic$146
  • Amgen$116
  • plus $388 from 12 others

What the payments were for

  • Travel & lodging$1,01521%
  • Food & beverage$3,62375%
  • Other$1764%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,815 in reported general payments places this provider in the 75th percentile of 93 plastic and reconstructive surgery providers in New Jersey.

See all plastic and reconstructive surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$98,018
Medicare patients
145
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin31$125
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$53
Tramadol Hcl22$40
Oxycodone Hcl13$35

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Red Bank

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →